View More Recent Stories
-
IceCure Medical (ICCM) announces key findings from three clinical studies of ProSense in treatment of breast cancer were presented
-
IceCure Medical Ltd (ICCM) Receives Nasdaq Non-compliance Notice
-
IceCure Medical (ICCM): European Study Provides More Evidence Supporting ProSense is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer
-
IceCure Medical Ltd (ICCM) Granted FDA Regulatory Clearance for Next-Gen XSense Cryoablation System
